Oral Micronized Progesterone and Imaging Contrast Dye: What You Need to Know Before Your Scan

Does Oral Micronized Progesterone Interact With Contrast Dye?

The short answer: no direct interaction between oral micronized progesterone and either iodinated or gadolinium-based contrast media has been identified in peer-reviewed pharmacokinetic studies or in the current Prometrium prescribing information. Prometrium's FDA-approved label lists sedative-hypnotics, CNS depressants, and CYP3A4/CYP2C19 modulators as the agent classes that meaningfully alter its plasma levels. Contrast agents belong to none of those classes.

That does not mean the appointment is risk-free. The risks that do exist center on the contrast agent itself and on any sedation or premedication you may receive during the procedure.

How Progesterone Is Metabolized

Oral micronized progesterone is absorbed through the gastrointestinal tract and undergoes first-pass hepatic metabolism, primarily via CYP3A4 and CYP2C19. Its major metabolites include 5-alpha-dihydroprogesterone and 3-alpha, 5-alpha-tetrahydroprogesterone (allopregnanolone), the latter of which carries sedative properties through positive allosteric modulation of GABA-A receptors. Peak serum concentrations occur roughly 3 hours after ingestion. One pharmacokinetic study in postmenopausal women confirmed that bioavailability of oral progesterone is substantially lower than intramuscular formulations due to this extensive first-pass effect.

How Contrast Agents Are Cleared

Iodinated contrast media used in CT imaging and gadolinium-based contrast agents (GBCAs) used in MRI are both cleared renally, with the majority excreted unchanged in urine within 24 hours in patients with normal renal function. The ACR Manual on Contrast Media specifies that these agents do not undergo hepatic CYP metabolism. Because progesterone's pharmacokinetics are governed entirely by hepatic pathways and GBCA/iodinated agent clearance is entirely renal, the two processes run in parallel without meaningful cross-interference.

The Sedation Overlap You Should Not Ignore

This is the one procedural concern worth flagging explicitly. Allopregnanolone, the active neuroactive metabolite of oral progesterone, potentiates GABA-A activity. If your imaging procedure involves conscious sedation with benzodiazepines (midazolam is common), propofol, or opioids, that GABAergic sedation may stack with progesterone's endogenous neuroactive metabolite. A 2016 review in the Journal of Clinical Endocrinology and Metabolism documented measurable allopregnanolone elevations following standard 200 mg oral progesterone doses. Tell your anesthesiologist or radiologist about your Prometrium dose and the timing of your last capsule.

Iodinated Contrast Agents and Progesterone: CT Scan Considerations

CT imaging with iodinated contrast is among the most common outpatient imaging procedures. Agents in this class include iohexol (Omnipaque), ioversol (Optiray), and iodixanol (Visipaque). None of these agents are metabolized by CYP enzymes, and none appear in the Prometrium interaction table.

Contrast-Induced Nephropathy: A Contrast Risk, Not a Progesterone Risk

Contrast-induced acute kidney injury (CI-AKI) remains the primary safety concern with iodinated agents. A meta-analysis published in JAMA Internal Medicine (N=13,638) found CI-AKI rates of approximately 6.4% in high-risk patients (pre-existing CKD, diabetes, dehydration). Progesterone itself does not damage renal tubules and does not potentiate CI-AKI. Your renal risk factors matter here, not your hormone prescription.

Hypersensitivity Reactions: Allergy History Is the Real Variable

Iodinated contrast can trigger anaphylactoid reactions ranging from urticaria to bronchospasm. Prometrium capsules contain peanut oil as an excipient. The FDA label states that Prometrium "should not be used in patients with known sensitivity to peanuts." Patients with peanut allergy taking Prometrium should already have disclosed this allergy to all treating clinicians. At a contrast imaging appointment, that disclosure matters because peanut allergy may signal a broader atopic profile that moderately elevates the risk of contrast hypersensitivity, even though the mechanism is not identical. ACR guidance recommends pre-medication with corticosteroids and antihistamines for patients with prior contrast reactions or high-risk atopic histories.

Metformin and Iodinated Contrast: A Lesson in Polypharmacy Awareness

Many women on Prometrium for HRT also take metformin for diabetes or PCOS. The ACR and American Diabetes Association guidelines recommend withholding metformin for 48 hours after iodinated contrast in patients with eGFR <30 mL/min/1.73 m² due to lactic acidosis risk. Progesterone does not require the same precaution, but the co-prescription means your radiology team needs a full medication list, not just the one that interacts.

Gadolinium-Based Contrast Agents and Progesterone: MRI Considerations

Gadolinium-based contrast agents (GBCAs) are the standard contrast medium for MRI scans. Approved agents include gadobutrol (Gadavist), gadoteridol (ProHance), and gadopentetate dimeglumine (Magnevist, now largely replaced by macrocyclic agents). Like iodinated agents, GBCAs are renally eliminated and do not interact with CYP3A4 or CYP2C19.

Nephrogenic Systemic Fibrosis: Kidney Function Is the Gate

The FDA's 2018 safety update on GBCAs confirmed that nephrogenic systemic fibrosis (NSF) risk is essentially confined to patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) and is independent of any co-administered medications. Progesterone does not impair renal elimination of gadolinium. NSF is not a progesterone-related concern.

Gadolinium Retention: What Current Evidence Shows

Linear GBCAs are associated with gadolinium deposition in brain tissue, confirmed in autopsy studies and detected on unenhanced T1 MRI as increased signal in the dentate nucleus and globus pallidus. A 2016 NEJM Perspective by Kanda et al. raised awareness of this phenomenon. Gadolinium retention has not been linked to co-administered hormones in any published dataset. Whether gadolinium deposition causes clinical harm in patients with normal renal function remains under active investigation.

Sedation During MRI: The Same GABA Overlap Applies

Patients with claustrophobia sometimes receive oral benzodiazepines (lorazepam 1 mg is common) before MRI. The GABA-A potentiation from allopregnanolone noted above applies here too. Take your usual Prometrium dose at its scheduled time and inform the technologist so sedation dosing can be adjusted if needed.

Oral Micronized Progesterone Drug Interactions: The Broader Picture

Understanding where contrast fits requires seeing the full interaction profile of Prometrium.

CYP3A4 and CYP2C19 Interactions

The Prometrium prescribing information identifies CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) as agents that reduce progesterone plasma levels and CYP3A4 inhibitors (ketoconazole, itraconazole) as agents that increase them. A 2003 pharmacology paper in Drug Metabolism and Disposition demonstrated that CYP3A4 plays a primary role in hydroxylation of progesterone to 16-alpha-hydroxyprogesterone. Contrast agents have no inhibitory or inductive effect on either enzyme.

CNS Depressants: The Clinically Relevant Class

Benzodiazepines, barbiturates, opioids, and alcohol all increase the sedative burden when combined with oral progesterone. A pharmacodynamic analysis published in Steroids confirmed that allopregnanolone concentrations are sufficient after standard Prometrium doses to produce measurable CNS effects. This is the interaction class that matters in an imaging context when sedation is planned.

Alcohol and Oral Micronized Progesterone

Alcohol warrants a specific note because patients frequently ask about it. Ethanol is both a CNS depressant and a mild CYP2C19 inhibitor at higher doses. Combining alcohol with Prometrium may increase allopregnanolone-mediated sedation and dizziness. The FDA label lists CNS depressants as requiring caution, and alcohol qualifies. On the day of any procedure requiring sedation or driving afterward, avoid alcohol entirely.

Hormone Therapy Co-Medications

Women using Prometrium as part of a combined HRT regimen also take estradiol (oral, patch, or gel). Estrogen can modestly induce CYP3A4, which may slightly increase progesterone metabolism. A study in Menopause (2014) found that combined estradiol/progesterone regimens were well tolerated without clinically significant mutual interference at standard doses, though plasma levels varied by route of estradiol delivery. This interaction is background context; it does not affect contrast safety.

Clinical Decision Framework: Oral Micronized Progesterone Around an Imaging Appointment

The table below summarizes the recommended approach based on scan type, sedation plan, and relevant patient variables.

| Scenario | Action for Progesterone | Reason | |---|---|---| | CT with iodinated contrast, no sedation | Continue dose on schedule | No pharmacokinetic interaction | | MRI with GBCA, no sedation | Continue dose on schedule | No pharmacokinetic interaction | | Any contrast study with conscious sedation (benzo/propofol) | Take dose at usual time; disclose to anesthesiologist | Allopregnanolone adds GABAergic load | | Peanut allergy noted on Prometrium | Disclose to radiology team before contrast | Atopic risk profile may affect pre-medication decision | | CKD (eGFR <30) on Prometrium | Contrast precautions per ACR/nephrologist | Renal issue, not progesterone issue | | Same-day metformin co-prescription | Follow ADA/ACR metformin hold protocol | Separate drug interaction with iodinated contrast | | Alcohol planned same day as procedure | Avoid alcohol | Additive CNS depression with allopregnanolone |

What to Tell Your Radiology and Imaging Team

Bring a current medication list to every imaging appointment. Your radiology team needs to know:

• The name of your medication (progesterone/Prometrium) and your daily dose (most commonly 100 mg or 200 mg)
• Whether you have a peanut allergy, since Prometrium contains peanut oil
• Whether you plan to take a benzodiazepine or have been prescribed sedation for the study
• Your most recent eGFR or creatinine if you have any kidney disease history

The ACR Manual on Contrast Media is the authoritative guideline radiologists use to assess pre-procedure risk. It does not list progesterone or progestogens as agents requiring special contrast precautions, which is consistent with the absence of any pharmacokinetic basis for interaction.

The Endocrine Society's 2022 clinical practice guideline on menopause hormone therapy, published in the Journal of Clinical Endocrinology and Metabolism, does not flag imaging procedures as a period requiring dose adjustment or interruption of progesterone therapy.

Dose and Timing Reference for Prometrium

Standard FDA-approved doses for Prometrium are 200 mg nightly (12 days per 28-day cycle) for endometrial protection in women with a uterus taking estrogen, or 400 mg nightly for secondary amenorrhea. The prescribing information recommends taking Prometrium at bedtime because the allopregnanolone metabolite causes drowsiness in many patients.

On the day of a contrast imaging study, take your dose at its usual scheduled time unless your prescribing clinician has specifically told you otherwise. No imaging-related dose hold is recommended in current FDA labeling or in published endocrinology guidelines.